The association between cryptococcal variety and immunocompetent and immunocompromised hosts

Pharmacotherapy

Volumn 18, Issue 2 I, 1998, Pages 255-264

  Peachey, Pamala R ^a   Gubbins, Paul O ^b,d   Martin, Rebecca E ^c  

^a Drug Information Center   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; FUNGUS ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CRYPTOCOCCOSIS; CRYPTOCOCCUS; CRYPTOCOCCUS NEOFORMANS; FUNGAL MENINGITIS; HUMAN; IMMUNOMODULATION; MEDICAL DECISION MAKING; REVIEW; STRAIN DIFFERENCE;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; SEROTYPING;

EID: 0031917584     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989;321:794-9.
2. Diamond RD. Cryptococcus neoformans. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 4th ed. New York: Churchill Livingstone, 1995: 2331-40.
3. Levitz SM. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis 1991;13: 1163-9.
4. Kwon-Chung KJ, Bennett JE. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol 1984;120:123-30.
5. Ellis DH, Pfeiffer TJ. Natural habitat of Cryptococcus neoformans var. gattii. J Clin Microbiol 1990;28:1642-4.
6. Pfeiffer TJ, Ellis DH. Environmental isolation of Cryptococcus neoformans var. gattii from Eucalyptus tereticornis. J Med Vet Mycol 1992;30:407-8.
7. Sorrell TC, Chen SCA, Ruma P, et al. Concordance of clinical and environmental isolates of Cryptococcus neoformans var. gattii by random amplification of polymorphic DNA analysis and PCR fingerprinting. J Clin Microbiol 1996;34:1253-60.
8. Rozenbaum R, Goncalves AJR, Wanke B, et al. Cryptococcus neoformans varieties as agents of cryptococcosis in Brazil. Mycopathologia 1992;119:133-6.
9. Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995;20:611-16.
10. Fisher D, Burrow J, Lo D, Currie B. Cryptococcus neoformans in tropical northern Australia: predominantly variant gattii with good outcomes. Aust N Z J Med 1993;23:678-82.
11. Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995;21:28-34.
12. Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis. A study of 111 cases. Ann Intern Med 1974;80:176-80.
13. Farmer SG, Komoromski RA. Histological response to capsule deficient Cryptococcus neoformans. Arch Pathol 1973;96:383-7.
14. Miller MF, Mitchell TG. Killing of Cryptococcus neoformans strains by human neutrophils and monocytyes. Infect Immunol 1991;59:24-8.
15. Buchanan KL, Murphy JW. Characterization of cellular infiltrations and cytokine production during expression phase of the anticryptococcal delayed-type hypersensitivity response. Infect Immunol 1993;61:2854-65.
16. Washburn RG, Bryant-Varela BJ, Julian NC, Bennett JE. Differences in Cryptococcus neoformans capsular polysaccharide structure influence assembly of alternative complement pathway C3 convertase on fungal surfaces. Mol Immunol 1991;28:465-70.
17. Dong ZM, Murphy JW. Intravascular cryptococcal culture filtrate (CneF) and its major component, glucuronoxylomannan, are potent inhibitors of leukocyte accumulation. Infect Immunol 1995;63:770-8.
18. Dong ZM, Murphy JW. Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils. J Clin Invest 1996;97:689-98.
19. Dong ZM, Murphy JW. Effects of the two varieties of Cryptococcus neoformans cells and culture filtrate antigens on neutrophil locomotion. Infect Immunol 1995;63:2632-44.
20. White MH, Armstrong D. Cryptococcosis. Infect Dis Clin North Am 1994;8(2):383-98.
21. Rozenbaum R, Goncalves AJR. Clinical epidemiological study of 171 cases of cryptococcosis. Clin Infect Dis 1994;18:369-80.
22. Mohr JA, Tatem BA, Long H, Muchmore HG, Felton FG. Increased susceptibility of Cryptococcus neoformans to amphotericin B in the presence of steroids. Sabouraudia 1973;11:140-2.
23. Mitchell DH, Sorrell TC. Pancoast's syndrome due to pulmonary infection with Cryptococcus neoformans var. gattii. Clin Infect Dis 1992;14:1142-4.
24. Ellis DH. Cryptococcus neoformans var. gattii in Australia. J Clin Microbiol 1987;25:430-1.
25. Lehman PF, Morgan RJ, Freimer EH. Infection with Cryptococcus neoformans var. gattii leading to pulmonary cryptococcoma and meningitis. J Infect 1984;9:301-6.
26. Emmons WW, Luchsinger S, Miller L. Progressive pulmonary cryptococcosis in a patient who is immunocompetent. South Med J 1995;88:657-60.
27. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992;326:83-9.
28. Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. Ann Intern Med 1990;113:183-7.
29. White M, Cirrincione Blevins A, Armstrong D. Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. J Infect Dis 1992;165:960-3.